Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide <scp>BCise</scp> : 6‐month follow‐up from <scp>US real‐world</scp> data

Abstract

At 6-month follow-up, a higher proportion of patients initiating dulaglutide were adherent to and persistent with their treatment, compared to matched patients initiating either semaglutide or exenatide BCise.